Literature DB >> 16305514

Drug tissue distribution: study methods and therapeutic implications.

J M Lanao1, M A Fraile.   

Abstract

Current interest in studies on tissue distribution stems from the limited capacity to predict tissue concentrations and the pharmacological response from plasma drug levels, and from the limitations - both methodological and deontological- involved in doing so, especially in humans. In this review we carry out a comparative analysis of the methods used for studying tissue distribution, placing special focus on recently developed non-invasive methods for the research of tissue distribution in humans, such as positron emission tomography and nuclear magnetic resonance spectroscopy. We describe the strategies of tissue distribution pharmacokinetic analysis that have evolved from analysis based on compartment and physiological models to analyses based on spatial and fractal models and, mainly, pharmacokinetic-pharmacodynamic models. Model-independent analysis based on the use of mean transit times or deconvolution strategies has become a good alternative for the pharmacokinetic analysis of tissue distribution. The need to increase the selectivity of many drugs justifies the desire to gain further insight into the design of new analogues prodrugs and carrier systems that will guarantee the specific delivery of a given drug to a particular organ or tissue, optimising the response. In silico models for drug distribution have become a helpful tool in drug discovery and development. The therapeutic implications of drug tissue distribution are also analysed, special reference being made to antiretroviral therapy and antitumoural gene therapy, among others.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16305514     DOI: 10.2174/138161205774580679

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  10 in total

Review 1.  Qualitative and quantitative mass spectrometry imaging of drugs and metabolites in tissue at therapeutic levels.

Authors:  Na Sun; Axel Walch
Journal:  Histochem Cell Biol       Date:  2013-07-24       Impact factor: 4.304

2.  Assessing drug and metabolite detection in liver tissue by UV-MALDI and IR-MALDESI mass spectrometry imaging coupled to FT-ICR MS.

Authors:  Jeremy A Barry; M Reid Groseclose; Guillaume Robichaud; Stephen Castellino; David C Muddiman
Journal:  Int J Mass Spectrom       Date:  2015-02-01       Impact factor: 1.986

3.  Mapping antiretroviral drugs in tissue by IR-MALDESI MSI coupled to the Q Exactive and comparison with LC-MS/MS SRM assay.

Authors:  Jeremy A Barry; Guillaume Robichaud; Mark T Bokhart; Corbin Thompson; Craig Sykes; Angela D M Kashuba; David C Muddiman
Journal:  J Am Soc Mass Spectrom       Date:  2014-04-18       Impact factor: 3.109

Review 4.  Future technology insight: mass spectrometry imaging as a tool in drug research and development.

Authors:  D F Cobice; R J A Goodwin; P E Andren; A Nilsson; C L Mackay; R Andrew
Journal:  Br J Pharmacol       Date:  2015-05-05       Impact factor: 8.739

5.  Tissue Distribution of Oleocanthal and Its Metabolites after Oral Ingestion in Rats.

Authors:  Anallely López-Yerena; Anna Vallverdú-Queralt; Olga Jáuregui; Xavier Garcia-Sala; Rosa M Lamuela-Raventós; Elvira Escribano-Ferrer
Journal:  Antioxidants (Basel)       Date:  2021-04-27

6.  A Nanostructured Matrices Assessment to Study Drug Distribution in Solid Tumor Tissues by Mass Spectrometry Imaging.

Authors:  Silvia Giordano; Valentina Pifferi; Lavinia Morosi; Melinda Morelli; Luigi Falciola; Giuseppe Cappelletti; Sonja Visentin; Simonetta A Licandro; Roberta Frapolli; Massimo Zucchetti; Roberta Pastorelli; Laura Brunelli; Maurizio D'Incalci; Enrico Davoli
Journal:  Nanomaterials (Basel)       Date:  2017-03-21       Impact factor: 5.076

7.  Detection and characterization of simvastatin and its metabolites in rat tissues and biological fluids using MALDI high resolution mass spectrometry approach.

Authors:  Wencui Yin; Reem I Al-Wabli; Mohamed W Attwa; A F M Motiur Rahman; Adnan A Kadi
Journal:  Sci Rep       Date:  2022-03-19       Impact factor: 4.379

Review 8.  Imaging mass spectrometry in drug development and toxicology.

Authors:  Oskar Karlsson; Jörg Hanrieder
Journal:  Arch Toxicol       Date:  2016-12-08       Impact factor: 5.153

9.  High-throughput high-volume nuclear imaging for preclinical in vivo compound screening§.

Authors:  Sven Macholl; Ciara M Finucane; Jacob Hesterman; Stephen J Mather; Rachel Pauplis; Deirdre Scully; Jane K Sosabowski; Erwan Jouannot
Journal:  EJNMMI Res       Date:  2017-04-07       Impact factor: 3.138

Review 10.  Animal models for target diseases in gene therapy--using DNA and siRNA delivery strategies.

Authors:  Ian S Blagbrough; Chiara Zara
Journal:  Pharm Res       Date:  2008-10-08       Impact factor: 4.200

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.